DRUCKEN

Lymphoma, Leukemia & HSCT

The UCT Mainz Program in Hematologic Malignancies is focusing on an efficient transfer of innovative findings in basic science into novel therapeutic strategies. As the sole certified transplantation center in Rhineland-Palatinate, we performed 179 hemopoietic stem cell transplants (HSCT) including 117 allogeneic HSCTs in 2018.

Clinical Research

Within our clinical research program, we performed 327 clinical trials including 33 phase I studies and enrolled 1,814 patients. Investigators of the UCT Mainz Program Hematologic Malignancies substantially contributed to pivotal national and international studies such as the analysis of Blinatumomab in non-Hodgkin lymphoma (Hess G., et al. JCO. 2016), the CASTOR trial in multiple myeloma (Munder M., et al. NEJM. 2016), Midostaurin in AML (Kindler T., et al. Blood. 2019).  

Translational Projects

Translational research within the program addresses cancer immunotherapy, leukemogenesis and genetic instability. Within the previous funding period a new DFG-funded Emmy-Noether group (M. Kühn) and a DKTK young investigator group (B. Guezguez) have been established. Further achievements include i) development of a unique transcutaneous vaccination method currently tested in an IIT (Radsak MP. Eur. J Immunol. 2019; patent: EP 18204287.9; see also B 2.); ii) identification of mechanisms of immune evasion during disease progression (Schrörs B., et al. Oncotarget. 2017), iii) generation of natural cytotoxicity receptor (NCR)-based CARs directed against AML cells for adoptive cellular immunotherapy (patent: EP 19180008.5) or v) identification of aberrant NCAM (CD56) expression as resistance marker and novel target in AML (Sasca D., et al. Blood. 2019). Current efforts aim at transferring our findings in basic research into investigator initiated, hypothesis-driven clinical trials.

Most significant publications since 2015